Literature DB >> 2207315

Release of tumor necrosis factor by human polymorphonuclear leukocytes.

J Y Djeu1, D Serbousek, D K Blanchard.   

Abstract

Evidence is presented that human polymorphonuclear neutrophils (PMN) can be induced to produce tumor necrosis factor (TNF). Other investigators have previously reported that TNF has been induced from macrophages by bacteria and, more recently, from natural killer cells by certain tumor cells. Our laboratory has reported that the opportunistic fungi, Candida albicans, can induce TNF, not only from human monocytes, but also from Percoll-fractionated large granular lymphocytes. We now report that incubation of PMN with C albicans for 3 hours was sufficient for detection of TNF release, and peak induction was observed at 8 to 18 hours. This release was inhibitable by actinomycin D, an inhibitor of RNA synthesis, as well as by emetine and cycloheximide, which block protein synthesis. The TNF produced by PMN was neutralized by specific monoclonal antibodies against human TNF. These results represent an important finding that TNF production is a normal response of PMN to stimulation by fungi such as C albicans and suggest that the release of TNF may be related to autocrine activation of PMN effector function to control Candida growth.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2207315

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Neutrophil depletion during Toxoplasma gondii infection leads to impaired immunity and lethal systemic pathology.

Authors:  S K Bliss; L C Gavrilescu; A Alcaraz; E Y Denkers
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Superior biocompatibility of heparin-bonded circuits in pediatric cardiopulmonary bypass.

Authors:  T Ozawa; K Yoshihara; N Koyama; S Yamazaki; Y Takanashi
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-12

3.  Potentiation of the respiratory burst of human neutrophils by cycloheximide: regulation of reactive oxidant production by a protein(s) with rapid turnover?

Authors:  R E Stringer; S W Edwards
Journal:  Inflamm Res       Date:  1995-04       Impact factor: 4.575

4.  N-formyl-methionyl-leucyl-phenylalanine (fMLP) inhibits tumour necrosis factor-alpha (TNF-alpha) production on lipopolysaccharide (LPS)-stimulated human neutrophils.

Authors:  M Vulcano; M F Alves Rosa; F S Minnucci; A C Cherñavsky; M A Isturiz
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

5.  Cytokine production of neutrophils is limited to interleukin-8.

Authors:  J Altstaedt; H Kirchner; L Rink
Journal:  Immunology       Date:  1996-12       Impact factor: 7.397

6.  Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients.

Authors:  F Ajello; R La Licata; M Lodato; F Vitale; F Bonura; R Valenti; M Bruno; N Romano
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

7.  In vivo role of phagocytic synovial lining cells in onset of experimental arthritis.

Authors:  P L Van Lent; A E Van den Hoek; L A Van den Bersselaar; M F Spanjaards; N Van Rooijen; C D Dijkstra; L B Van de Putte; W B Van den Berg
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

8.  Polymorphonuclear leukocytes as a significant source of tumor necrosis factor-alpha in endotoxin-challenged lung tissue.

Authors:  Z Xing; H Kirpalani; D Torry; M Jordana; J Gauldie
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

9.  Differential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans.

Authors:  E Blasi; R Barluzzi; R Mazzolla; F Bistoni
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

10.  LPS-induced 111In-eosinophil accumulation in guinea-pig skin: evidence for a role for TNF-alpha.

Authors:  V B Weg; D T Walsh; L H Faccioli; T J Williams; M Feldmann; S Nourshargh
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.